Document is current
Any future updates will be listed below
-
Authors
Dhakal, Binod https://orcid.org/0000-0002-4377-9742
Hari, Parameswaran
Chhabra, Saurabh
Szabo, Aniko
Lum, Lawrence G https://orcid.org/0000-0001-7561-6035
Glass, Deborah D
Park, Jee Hyun
Donato, Michele
Siegel, David S
Felizardo, Tania C
Fowler, Daniel H
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04176380 at ClinicalTrials.govnct04176380 at ClinicalTrials.govDocuments that mention this clinical trial
Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma
https://doi.org/10.1136/jitc-2024-010649
nct04176380 at ClinicalTrials.govDocuments that mention this clinical trial
Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma
https://doi.org/10.1136/jitc-2024-010649
nct04176380 at ClinicalTrials.govDocuments that mention this clinical trial
Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma
https://doi.org/10.1136/jitc-2024-010649
nct05144698 at ClinicalTrials.govDocuments that mention this clinical trial
Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma
https://doi.org/10.1136/jitc-2024-010649
Documents that mention this clinical trial
1028 Ex vivo chemotherapy resistance of metabolically reprogrammed autologous Th1/Tc1 cells (RAPA-201): Towards the clinical translation of immune-sparing host conditioning
https://doi.org/10.1136/jitc-2023-sitc2023.1028
Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma
https://doi.org/10.1136/jitc-2024-010649
- License Information
